Our Mission
MD Anderson
UT Southwestern
Beth Israel
University of Michigan
University of Pennsylvania
Vanderbilt University
Duke University
With seven partner institutions, each with a strong background of scientific and clinical leadership in RCC research, the Kidney Cancer Research Consortium has the unique infrastructure required to perform multicenter, tissue-rich, transformative clinical trials.
Commitment & Experience
The Kidney Cancer Research Consortium (KCRC) was founded in 2018 through the Department of Defense Consortium Development Award and was subsequently awarded the DoD Clinical Consortium Award in 2020.
Information for Patients
Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.
Research News
Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.
There is an urgent need for new RCC therapies.
The Kidney Cancer Research Consortium provides the research expertise and institutional infrastructure necessary to perform multicenter, tissue-rich, transformative clinical trials.
LEARN MORE
Ipilimumab, Nivolumab, and Ciforadenant as First-Line Therapy for Stage IV Renal Cell Carcinoma
Cost-Effective Access to Multicenter Expertise:
University of Michigan
Dr. Ulka Vaishampayan
Duke University
Dr. Daniel George
MD Anderson
Dr. Eric Jonasch
UT Southwestern
Dr. Hans Hammers
University of Pennsylvania
Dr. Naomi Haas
Beth Israel Deaconess
Dr. David McDermott
Vanderbilt University
Dr. Brian Rini
“We have senior researchers doing very good things, and I’m excited to see a new generation of researchers who are taking kidney cancer treatment to the next level. I’m convinced that in the next 5-10 years, we’re going to see tremendous advances.”
– Dr. Eric Jonasch, KCRC Principal Investigator